Literature DB >> 22552457

JC virus-associated central nervous system diseases in HIV-infected patients in Brazil: clinical presentations, associated factors with mortality and outcome.

Felipe Piza1, Maria Cristina Fink, Gilberto S Nogueira, Claudio S Pannuti, Augusto C Penalva de Oliveira, José Ernesto Vidal.   

Abstract

INTRODUCTION: Several presentations of neurologic complications caused by JC virus (JCV) in human immunodeficiency virus (HIV)-infected patients have been described and need to be distinguished from the "classic" form of progressive multifocal leukoencephalopathy (PMl). The objectives of this study were: 1) to describe the spectrum and frequency of presentations of JCV-associated central nervous system (CNS) diseases; 2) identify factors associated with in-hospital mortality of patients with JCV-associated CNS disease; and 3) to estimate the overall mortality of this population.
MATERIAL AND METHODS: This was a retrospective study of HIV-infected patients admitted consecutively for JCVassociated CNS diseases in a referral teaching center in São Paulo, Brazil, from 2002 to 2007. All patients with laboratory confirmed JCV-associated CNS diseases were included using the following criteria: compatible clinical and radiological features associated with the presence of JCV DNA in the cerebrospinal fluid. JCV-associated CNS diseases were classified as follows: 1) classic PMl; 2) inflammatory PMl; and 3) JC virus granule cell neuronopathy (GCN).
RESULTS: We included 47 cases. JCV-associated CNS diseases were classified as follows: 1) classic PMl: 42 (89%); 2) inflammatory PMl: three (6%); and 3) JC virus GCN: four (9%). Nosocomial pneumonia (p = 0.003), previous diagnosis of HIV infection (p = 0.03), and imaging showing cerebellar and/or brainstem involvement (p = 0.02) were associated with in-hospital mortality. overall mortality during hospitalization was 34%.
CONCLUSIONS: Novel presentations of JCV-associated CNS diseases were observed in our setting; nosocomial pneumonia, previous diagnosis of HIV infection, and cerebellar and/or brainstem involvement were associated with in-hospital mortality; and overall mortality was high.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22552457

Source DB:  PubMed          Journal:  Braz J Infect Dis        ISSN: 1413-8670            Impact factor:   1.949


  6 in total

1.  A hitherto unrecognised case of progressive multifocal leukoencephalopathy.

Authors:  Huey Kuan Tan; Chun Hong Tang
Journal:  BMJ Case Rep       Date:  2015-07-23

2.  Not a Disease of the Past: A Case Series of Progressive Multifocal Leukoencephalopathy in the Established Antiretroviral Era.

Authors:  Nathan A Summers; Colleen F Kelley; Wendy Armstrong; Vincent C Marconi; Minh Ly Nguyen
Journal:  AIDS Res Hum Retroviruses       Date:  2019-04-03       Impact factor: 2.205

3.  Association of neurotropic viruses in HIV-infected individuals who died of secondary complications of tuberculosis, cryptococcosis, or toxoplasmosis in South India.

Authors:  Rajesh Kannangai; Jaiprasath Sachithanandham; Anita Mahadevan; Asha Mary Abraham; Gopalan Sridharan; Anita Desai; Vasanthapuram Ravi; Susarla Krishna Shankar
Journal:  J Clin Microbiol       Date:  2013-01-02       Impact factor: 5.948

4.  Gone over to the dark side: Natalizumab-associated JC virus infection of neurons in cerebellar gray matter.

Authors:  Xin Dang; Igor J Koralnik
Journal:  Ann Neurol       Date:  2013-10       Impact factor: 10.422

Review 5.  Heterogeneous imaging characteristics of JC virus granule cell neuronopathy (GCN): a case series and review of the literature.

Authors:  Martijn T Wijburg; Bob W van Oosten; Jean-Luc Murk; Ouafae Karimi; Joep Killestein; Mike P Wattjes
Journal:  J Neurol       Date:  2014-10-09       Impact factor: 6.682

6.  JC virus/human immunodeficiency virus 1 co-infection in the Brazilian Amazonian region.

Authors:  Izaura Maria Vieira Cayres-Vallinoto; Antonio Carlos Rosário Vallinoto; Giselle Priscila Dos Anjos Pena; Vânia Nakauth Azevedo; Luiz Fernando Almeida Machado; Marluísa de Oliveira Guimarães Ishak; Ricardo Ishak
Journal:  Braz J Infect Dis       Date:  2016-06-05       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.